2020

08.05.2020 – HBM Healthcare Investments AG

HBM Healthcare Investments nominates Dr Stella X. Xu for the Board of Directors

Media Release

Zug, 8 May 2020

HBM Healthcare Investments nominates Dr Stella X. Xu for the Board of Directors

The Board of Directors of HBM Healthcare Investments AG proposes Dr Stella X. Xu for the election to the Board of Directors. Dr Xu is a proven expert in investing in innovative healthcare companies, with in-depth knowledge of the pharmaceutical sector in the key US and Chinese markets.

Since 2017, Dr Xu has been Managing Director of Quan Capital, a venture fund specialising in life sciences with offices in China and the USA. Prior to that, she worked for Roche for 15 years in various roles in the USA and China. Her last role there, as a core member of the global management team for research and early development in Immunology, Inflammation and Infectious Diseases, involved heading up Roche's Innovation Centre in Shanghai with around 200 scientists. Before joining Roche, Dr Xu spent four years at McKinsey & Company in the USA, where she was responsible for strategic projects in the healthcare sector.

Stella Xu received her PhD in Immunology from Northwestern University in Illinois, USA, and completed her undergraduate studies in Biophysics and Physiology at Peking University in Beijing. She is currently a board member of NextCure and a few private biotech companies.

All current board members are standing for re-election at the Annual General Meeting.


Contact
For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com.


close